Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas(University of California, Los Angeles), Caroline Robert(Institut Gustave Roussy), Adil Daud(University of California, San Francisco), Maxine Giannotti(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hassane M. Zarour(University of Pittsburgh), Brianna Hoffner(University of Colorado Cancer Center), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Bartosz Chmielowski(UCLA Health), Jeffrey S. Weber(NYU Langone Health), Donald P. Lawrence(Massachusetts General Hospital), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alain P. Algazi(University of California, San Francisco), Naiyer A. Rizvi(Synthego (United States)), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Xiaoyun Li(Nanjing University), Tara C. Gangadhar(University of Pennsylvania), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jill A. Lindia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christine Mateus(Centre National de la Recherche Scientifique)
Cited by 1,069
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k